CONMED Corporation reports news on its medical technology business, which provides surgical devices and equipment used by surgeons and other healthcare professionals across multiple specialties. Company updates commonly cover sales trends, domestic and international revenue, GAAP and adjusted earnings, full-year outlooks, and management presentations in the healthcare sector.
Recurring announcements also address portfolio optimization, including the exit or reduction of certain gastroenterology products, and the company’s focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. Other corporate news includes finance leadership changes and operating initiatives tied to supply chain execution, product rationalization, and margin profile.
CONMED (NYSE: CNMD) will report first quarter 2026 financial results after market close on April 29, 2026. Management will host a conference call at 4:30 p.m. ET the same day.
Investors can pre-register for telephone access, join a live webcast via the company's Investors page at www.conmed.com, and view a replay approximately one hour after the call ends.
CONMED (NYSE: CNMD) reported Q4 2025 sales of $373.2M (+7.9% YoY) and full-year 2025 sales of $1,374.7M (+5.2% YoY). GAAP diluted EPS was $0.54 in Q4 and $1.51 for FY 2025; adjusted diluted EPS were $1.43 (Q4) and $4.59 (FY).
The company issued 2026 guidance of revenue between $1.345B–$1.375B and adjusted diluted EPS of $4.30–$4.45, noting a modest currency tailwind and organic growth excluding gastroenterology sales.
CONMED (NYSE: CNMD) announced that Todd Garner will step down as Chief Financial Officer effective March 15, 2026 and will remain in an advisory role through November 2, 2026. The company has started a comprehensive search, supported by a leading executive search firm, to identify a new CFO. Management thanked Garner for eight years of service and said his departure is not related to any disagreement over financial statements or disclosures. CONMED also reaffirmed its full-year 2025 consolidated revenue and adjusted EPS guidance previously issued on November 5, 2025.
CONMED (NYSE: CNMD) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:00 p.m. PT / 6:00 p.m. ET in San Francisco.
Presenters will be Patrick J. Beyer, president and CEO, and Todd W. Garner, EVP and CFO. A live audio webcast will be available via the company’s Investors page at www.conmed.com, with a replay accessible after the event.
CONMED (NYSE: CNMD) will report fourth quarter 2025 financial results after market close on January 28, 2026. Management will host a conference call the same day at 4:30 p.m. ET to discuss results.
Investors can pre-register for telephone access to receive a dial-in number and passcode. The call will be webcast from the Investors section at www.conmed.com, and a webcast replay will be available about one hour after the call ends.
CONMED (NYSE: CNMD) announced it will exit its gastroenterology product lines and conclude its U.S. and Canadian distribution agreement for the Gore® VIABIL® biliary stent effective January 1, 2026. The company expects gastroenterology to generate $90–$95 million in 2025 with gross margins near 45%. CONMED forecasts EPS dilution of $0.45–$0.55 in 2026 from the exit and an improvement to consolidated gross margin of approximately +80 basis points after the exit completes. Proceeds from the Gore transaction are planned for general corporate purposes including strategic investments, debt paydown, and share repurchases. CONMED reaffirmed its 2025 revenue guidance of $1.365–$1.372 billion and adjusted EPS $4.48–$4.53, and will provide full 2026 guidance on its Q4 2025 earnings call.
CONMED (NYSE: CNMD) reported Q3 2025 sales of $337.9M, up 6.7% YoY (6.3% constant currency). GAAP diluted EPS was $0.09 vs. $1.57 a year ago; adjusted diluted EPS was $1.08 vs. $1.05 a year ago. Gross margin declined to 49.2% from 56.5% in Q3 2024. The Board authorized a $150.0M share repurchase program, suspended the quarterly cash dividend, and expects to repurchase at least $25.0M annually beginning in 2026.
Full-year 2025 revenue guidance is updated to $1.365B–$1.372B. Adjusted diluted EPS guidance is $4.48–$4.53 (FX headwind ~$0.10); recent tariffs are estimated to reduce Q4 EPS by ~$0.07. Management held a conference call on Nov 5, 2025.
CONMED (NYSE: CNMD) will report Q3 2025 financial results after market close on Wednesday, November 5, 2025. Management will host a conference call at 4:30 p.m. ET the same day to discuss results. Participants can pre-register by phone to obtain dial-in number and passcode. The call will be webcast from the Investors section at www.conmed.com. A webcast replay will be available on the same site approximately one hour after the end of the call.
CONMED Corporation (NYSE: CNMD) has appointed Kim Kelderman to its Board of Directors, effective September 8, 2025. Kelderman currently serves as President, CEO, and Board member of Bio-Techne (NASDAQ: TECH) since February 2024.
Kelderman brings extensive experience in life sciences, having previously held leadership positions at Thermo Fisher Scientific, where he led multiple businesses and managed the Platforms and Content of the Genetic Sciences Division. Prior to that, he served as Senior Segment Leader at Becton Dickinson, overseeing the global Blood Tubes "Vacutainer" business.
CONMED Corporation (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share. The dividend was declared by the Board of Directors on August 7, 2025. Shareholders of record as of September 15, 2025 will receive the dividend payment on October 3, 2025.